多重PCR快速检测弥漫性大B细胞淋巴瘤患者骨髓BCL2/IGH与BCL6/IGH融合基因的临床意义

摘要

弥漫性大B细胞淋巴瘤(DLBCL)是最常见的侵袭性非霍奇金淋巴瘤,其临床表现、分子生物学特点都有显著的异质性.本研究旨在探讨多重PCR技术在DLBCL患者骨髓BCL2/IGH及BCL6/IGH等融合基因检测中的临床意义.利用多重巢式PCR技术对80例初治DLBCL患者的骨髓标本进行BCL2/IGH及BCL6/IGH融合基因检测.结果表明,80例患者骨髓标本中携带目的融合基因共12例,阳性率为15％；其中BCL2-IGH阳性患者为6例,BCL6-IGH阳性患者为6例.DLBCL患者携带不同的融合基因具有不同的临床特点.结论:运用多重PCR方法对DLBCL患者进行分子生物学检测具有快速、准确的优点.但需进一步深入研究改善方法,使之对融合基因能做定量或半定量分析,这对于DLBCL患者的诊断、协助分期、预后评估、微小残留病变的估测,指导临床治疗DLBCL有重要意义.%Diffuse large B cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL) , characterized by great heterogeneity in clinical manifestations and molecular genetics. This study was aimed to explore the clinical significance of applying multiplex PCR to detect BCL2/IGH and BCL6/IGH fusion genes in DLBCL. Multiplex PCR was used to detect bone marrow samples from 80 cases of DLBCL. The results showed that 12 patients (15% ) carried BCL2/IGH or BCL6/IGH fusion genes, BCL2/IGH was found in 6 patients (7. 5% ), and BCL6/IGH in another 6 patients (7.5% ). The patients with different molecular markers displayed-different clinical features and outcomes. It is concluded that multiple PCR is rapid and accurate method to identify gene abnormalities in DLBCL, but further studing a quantitative or semi-quantitative assay for the expression of fusion genes is needed.